This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Axsome Therapeutics, Inc. -1.91%
Ionis Pharmaceuticals, Inc. -0.45%
NETSTREIT Corp. +1.74%
BeiGene Ltd ADR +0.76%
Reddit, Inc. Class A -0.13%

Axsome Therapeutics, Inc.

AXSM

168.50

-1.91%

Ionis Pharmaceuticals, Inc.

IONS

74.79

-0.45%

NETSTREIT Corp.

NTST

19.25

+1.74%

BeiGene Ltd ADR

ONC

310.79

+0.76%

Reddit, Inc. Class A

RDDT

136.00

-0.13%

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • HC Wainwright & Co. analyst Mitchell Kapoor initiated coverage on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) with a Buy rating and announced a price target of $45. Ionis Pharmaceuticals shares closed at $27.09 on Friday. See how other analysts view this stock.
  • Jefferies analyst Andrew Tsai initiated coverage on Axsome Therapeutics, Inc. (NASDAQ:AXSM) with a Buy rating and announced a price target of $200. Axsome Therapeutics shares closed at $98.86 on Friday. See how other analysts view this stock.
  • Wells Fargo analyst John Kilichowski initiated coverage on NETSTREIT Corp. (NYSE:NTST) with an Overweight rating and announced a price target of $18. Netstreit shares closed at $15.28 on Friday. See how other analysts view this stock.
  • Truist Securities analyst Youssef Squali initiated coverage on Reddit, Inc. (NYSE:RDDT) with a Buy rating and announced a price target of $150. Reddit shares closed at $86.91 on Friday. See how other analysts view this stock.
  • RBC Capital analyst Greg Renza initiated coverage on BeiGene, Ltd. (NASDAQ:ONC) with an Outperform rating and announced a price target of $312. BeiGene shares closed at $238.51 on Friday.  See how other analysts view this stock.

Considering buying RDDT stock? Here’s what analysts think:

Read This Next:

  • How To Earn $500 A Month From Walgreens Stock Ahead Of Q2 Earnings

Photo via Shutterstock

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.